Related Experiment Video
Updated: May 10, 2025

Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
Multi-Omics Analysis of Survival-Related Splicing Factors and Identifies CRNKL1 as a Therapeutic Target in Esophageal
Tianrui Gao1,2, Meiling Fan1,2, Zhongyuan Zeng3
1State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Abstract:
Background: RNA alternative splicing represents a pivotal regulatory mechanism of eukaryotic gene expression, wherein splicing factors (SFs) serve as key regulators. Aberrant SF expression drives oncogenic splice variant production, thereby promoting tumorigenesis and malignant progression. However, the biological functions and potential targets of SFs remain largely underexplored. Methods: Through multi-omics analysis, we identified survival-related splicing factors (SFs) in esophageal cancer and elucidated their biological regulatory networks. To further investigate their downstream splicing targets, we combined alternative splicing events resulting from SF knockdown with those specific to esophageal cancer. Finally, these splicing events were validated through full-length RNA sequencing and confirmed in cancer cells and clinical specimens. Result: We identified six SFs that are highly expressed in esophageal cancer and correlate with poor prognosis. Further analysis revealed that these factors are significantly associated with immune infiltration, cancer stemness, tumor heterogeneity, and drug resistance. CRNKL1 was identified as a hub SFs. The target genes and pathways regulated by these SFs showed substantial overlap, suggesting their coordinated roles in promoting cancer stemness and metastasis. Specifically, alternative splicing of key markers, such as CD44 and CTTN, was regulated by most of these SFs and correlated with poor prognosis. Conclusions: Our study unveils six survival-related SFs that contribute to the aggressiveness of esophageal cancer and CTTN and CD44 alternative splicing may act as common downstream effectors of survival-related SFs. This study provides mechanistic insights into SF-mediated tumorigenesis and highlight novel therapeutic vulnerabilities in esophageal cancer.
Insights
Six survival-related splicing factors (SFs) drive esophageal cancer aggressiveness by promoting stemness and metastasis. Their targets, including CD44 and CTTN, offer potential therapeutic strategies for this cancer.
Area of Science:
- Molecular Biology
- Oncology
- Gene Regulation
Background:
- RNA alternative splicing is crucial for gene expression, with splicing factors (SFs) as key regulators.
- Dysregulated SFs contribute to cancer by producing oncogenic splice variants, but their roles are not fully understood.
- Esophageal cancer progression is linked to aberrant SF activity.
Purpose of the Study:
- Identify survival-related SFs in esophageal cancer.
- Elucidate their biological networks and downstream targets.
- Investigate their role in tumor aggressiveness and identify therapeutic vulnerabilities.
Main Methods:
- Multi-omics analysis to identify SFs and their networks in esophageal cancer.
- Combined SF knockdown splicing events with cancer-specific splicing events.
- Validated splicing events using full-length RNA sequencing in cell lines and clinical samples.
Main Results:
- Identified six highly expressed SFs correlating with poor esophageal cancer prognosis.
- These SFs are linked to immune infiltration, cancer stemness, heterogeneity, and drug resistance.
- CRNKL1 identified as a hub SF; CD44 and CTTN alternative splicing regulated by SFs, correlating with poor prognosis.
Conclusions:
- Unveiled six survival-related SFs driving esophageal cancer aggressiveness.
- CTTN and CD44 alternative splicing are common downstream effectors of these SFs.
- Provides mechanistic insights into SF-mediated tumorigenesis and highlights therapeutic targets in esophageal cancer.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Abnormal Proliferation

